CEACAM5 and neoplasm: (93), established seven PDOs from treatment-refractory metastatic CRC and one from a treatment naïve primary CRC, to investigate on resistance and sensitivity mechanisms of cibisatamab, a bispecific monoclonal antibody that binds carcino-embryonic antigen (CEA) on tumor cells and CD3 on T cells.